Package Leaflet: Information for the Patient
Paliperidone Teva 3 mg prolonged-release tablets EFG
Paliperidone Teva 6 mg prolonged-release tablets EFG
Paliperidone Teva 9 mg prolonged-release tablets EFG
Read the entire package leaflet carefully before you start taking this medicine, because it contains important information for you.
Contents of the package leaflet
Contents of the pack and further information
Paliperidone Teva contains the active substance paliperidone, which belongs to a class of medicines called antipsychotics.
Paliperidone is used to treat schizophrenia in adults and adolescents aged 15 years and older.
Schizophrenia is a disorder that causes symptoms such as hearing, seeing, or feeling things that do not exist, having false beliefs, being unusually suspicious, becoming withdrawn, having disorganized speech, and a flattening of emotions and behavior. People with this disorder may also feel depressed, anxious, guilty, or tense.
Paliperidone is also used to treat schizoaffective disorder in adults.
Schizoaffective disorder is a mental condition where people experience several of the symptoms of schizophrenia (listed above) as well as symptoms of mood disorders (feeling elated, depressed, agitated, restless, insomnia, talkativeness, loss of interest in daily activities, excessive or reduced sleep or food intake, and recurring thoughts of suicide).
Paliperidone can help alleviate the symptoms of your illness and prevent them from coming back.
Do not takepaliperidone
Warnings andprecautions
Talk to your doctor or pharmacist before taking paliperidone.
If you have any of these diseases, please consult your doctor, as it may be necessary to adjust your dose or keep you under observation for a while.
Because it has been rarely observed in patients treated with paliperidone that a dangerously low number of a type of white blood cells necessary to fight infections in the blood, your doctor may check the number of white blood cells.
Paliperidone may cause you to gain weight. Significant weight gain can negatively affect your health. Your doctor will regularly monitor your weight.
In patients treated with paliperidone, diabetes mellitus or worsening of pre-existing diabetes mellitus has been observed, your doctor should check for signs of high blood sugar. In patients with pre-existing diabetes mellitus, blood sugar should be regularly monitored.
During eye surgery for cataracts, the pupil (the black circle in the middle of the eye) may not increase in size as needed. Additionally, the iris (the colored part of the eye) may become flaccid during surgery, which can cause damage to the eye. If you are considering eye surgery, make sure to inform your ophthalmologist that you are using this medicine.
Children andadolescents
Paliperidone should not be given to children and adolescents under 15 years of age for the treatment of schizophrenia.
Paliperidone should not be given to children and adolescents under 18 years of age for the treatment of schizoaffective disorder.
This is because it is not known if paliperidone is safe or effective in this age group.
Othermedicines and paliperidone
Tell your doctor or pharmacist if you are using, have recently used, or might use other medicines.
Abnormalities in heart function may appear when taking this medicine with other medicines to control heart rhythm or other medicines such as antihistamines, antimalarials, or antipsychotics.
Since this medicine acts mainly on the brain, it may interfere with other medicines (or alcohol) that also act on it, due to the sum of effects on brain function.
This medicine may lower blood pressure, so you should be careful if you take this medicine with other medicines that also lower blood pressure.
This medicine may reduce the effect of medicines for Parkinson's disease and restless legs syndrome (e.g., levodopa).
The effects of this medicine may be affected if you take medicines that influence the speed of intestinal movement (e.g., metoclopramide).
A reduction in the dose of this medicine should be considered when it is administered at the same time as valproate.
The use of oral risperidone with this medicine is not recommended, as this combination may cause an increase in side effects.
Paliperidone should be used with caution with medicines that increase the activity of the central nervous system (psychostimulants such as methylphenidate).
Taking paliperidone with alcohol
You should avoid consuming alcohol during treatment with this medicine.
Pregnancy andbreast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
You should not take this medicine during pregnancy unless you have discussed it with your doctor.
The following symptoms may occur in newborn babies of mothers who have been treated with paliperidone in the last trimester of pregnancy (the last three months of pregnancy): shaking, stiffness, and/or muscle weakness, drowsiness, agitation, breathing problems, and feeding difficulties. If your baby develops any of these symptoms, you should contact your doctor.
You should not breast-feed while taking this medicine.
Driving and usingmachines
Dizziness and vision problems (see section 4, Possible side effects) may occur during treatment with this medicine. This should be taken into account when requiring maximum attention, for example, when driving or operating machinery.
Paliperidone Teva contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet, which can be considered as "sodium-free".
Take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, ask your doctor or pharmacist again.
Use inadults
The recommended dose in adults is 6 mg once a day in the morning. Your doctor may increase or decrease the dose within the dosage range of 3 mg to 12 mg once a day in the case of schizophrenia or 6 mg to 12 mg once a day in the case of schizoaffective disorder. This depends on how well the medicine works for you.
Use inadolescents
The recommended starting dose for the treatment of schizophrenia in adolescents aged 15 years and older is 3 mg once a day in the morning.
For adolescents who weigh 51 kg or more, the dose may be increased within the range of 6 mg to 12 mg once a day.
For adolescents who weigh less than 51 kg, the dose may be increased to 6 mg once a day.
Your doctor will decide how much you should take. The amount you take depends on how well the medicine works for you.
How and when to take paliperidone
This medicine should be taken orally, swallowed whole with water or other liquids. It should not be chewed, divided, or crushed.
This medicine should be taken in the morning with breakfast or on an empty stomach, but in the same way every day. Do not alternate between taking the medicine one day with breakfast and the next day on an empty stomach.
The active substance, paliperidone, is released once swallowed, and the tablet coating is eliminated from the body through the feces.
Patient withkidney problems
Your doctor may adjust the dose of this medicine according to your kidney function.
Elderly patients
Your doctor may reduce your dose of medicine if your kidney function is reduced.
If you take more paliperidone than you should
In case of overdose or accidental ingestion, consult your doctor, pharmacist, or go to the nearest hospital immediately, or call the Toxicology Information Service. Phone: 91 562 04 20, indicating the medicine and the amount taken. You may experience drowsiness, fatigue, abnormal body movements, problems standing and walking, dizziness due to low blood pressure, and changes in heartbeats.
If you forget to take paliperidone
Do not take a double dose to make up for forgotten doses. If you forget a dose, take the next dose the next day. If you forget two doses or more, contact your doctor.
If you stop taking paliperidone
Do not stop taking this medicine, as you will lose the effects of the medicine. You should not stop taking this medicine unless your doctor tells you to, as your symptoms may come back.
If you have any further questions about the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Report immediately to your doctorif:
Very common (may affect more than 1 in 10 patients)
Common adverse effects (may affect up to 1 in 10 patients)
Uncommon adverse effects (may affect up to 1 in 100 patients)
Rare adverse effects (may affect up to 1 in 1,000 patients)
Unknown frequency (frequency cannot be estimated from available data)
If you experience adverse effects, consult your doctor, pharmacist, or nurse, even if they are adverse effects that do not appear in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging and blister after CAD or EXP. The expiration date is the last day of the month indicated.
Store in the original packaging to protect it from moisture.
This medicine does not require special temperature conditions for storage.
Medicines should not be thrown down the drain or into the trash. Deposit the packaging and medicines you no longer need in the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This way, you will help protect the environment.
Composition of Paliperidone Teva
The active ingredient is paliperidone. Each prolonged-release tablet contains 3 mg, 6 mg, or 9 mg of paliperidone.
The other components are macrogol, butylhydroxytoluene, povidone, sodium chloride, microcrystalline cellulose, magnesium stearate, red iron oxide (E172), hydroxypropylcellulose, and cellulose acetate in the core of the tablet, and hypromellose, titanium dioxide (E171), talc, and propylene glycol in the coating and ink, black iron oxide (E172), and propylene glycol in the printing ink. See section 2. "Paliperidone Teva contains sodium."
Appearance of the Product and Package Contents
3 mg: Film-coated tablets, round, biconvex, white to grayish-white, with possible uneven surface and printed with the mark P3 on one side of the tablet. Diameter: approximately 9 mm.
6 mg: Film-coated tablets, round, biconvex, yellowish-brown, with possible uneven surface and printed with the mark P6 on one side of the tablet. Diameter: approximately 9 mm.
9 mg: Film-coated tablets, round, biconvex, light pink, with possible uneven surface and printed with the mark P9 on one side of the tablet. Diameter: approximately 9 mm.
Paliperidone Teva is available in boxes containing:
10x1, 14x1, 28x1, 30x1, 56x1, 98x1, 112x1, or 196x1 prolonged-release tablets in single-dose perforated blisters.
Not all pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
Teva B.V.
Swensweg 5
Haarlem 2031GA
Netherlands
Manufacturer:
KRKA, d.d., Novo mesto
Šmarješka cesta 6
8501
Slovenia
Or
Teva Pharma, S.L.U.
C/ C, nº 4. Polígono Industrial Malpica
50016 Zaragoza
Spain
Or
Laboratoria Qualiphar NV (Qualiphar NV)
Rijksweg 9
2880 Bornem
Belgium
You can request more information about this medicine by contacting the local representative of the Marketing Authorization Holder:
Teva Pharma, S.L.U.
c/ Anabel Segura 11, Edificio Albatros B, 1ª planta, Alcobendas,
28108 Madrid (Spain)
Date of the last revision of this leaflet: November 2024
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of PALIPERIDONE TEVA 3 mg PROLONGED-RELEASE TABLETS in October, 2025 is around 27.58 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.